Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy
Autoimmune Hemolytic Anemia
Explore 11 assets in Autoimmune Hemolytic Anemia →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Beijing Boren Hospital
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07361094CT.gov Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autoimmune Hemolytic Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy (this asset) | Beijing Boren Hospital | P1 | CC · 43 |
| Cyclophosphamide | City of Hope Medical Center | P2 | B |
| Nivestim | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | P2 | B |
| Acalabrutinib | City of Hope Medical Center | P2 | CCC |
| Ibrutinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | P2 | CCC |
| Prednisone | City of Hope Medical Center | P2 | CCC |
| Thiotepa | University of Florida | P1/2 | CCC |
| Bcma Car T Cells | Zhejiang University | Early P1 | C |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fairview University Medical Center | N/A | D |
+5 more in the Autoimmune Hemolytic Anemia cohort
Other indications for Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Systemic Lupus Erythematosus | — | P1 | CC · 43 |
| Systemic Sclerosis | — | P1 | CC · 43 |
| Idiopathic Inflammatory Myopathy | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy in Autoimmune Hemolytic Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-cd19-bcma-dual-target-car-t-cell-therapy-autoimmune-hemolytic-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →